How Is It Related to Cancer, and What Can Be Done About It? SDH is a protein that is based in the mitochondria. Its loss causes a major energy and metabolic crisis. Despite this, some [...]
Josalin Dunn Cancer. We all know someone who has it or we know someone who knows someone who has it. Either way, it’s a subject that is kind of taboo. Firstly, the [...]
Ellen Mayer, LRG member, recently participated in the Lilly Oncology On Canvas Art Competition in Vanderbilt Hall in Grand Central Station. Individual artists were invited to tell the story of their cancer journey on canvas. [...]
A recent article by Lindsey Cook on the US News and World Report blog discusses the value of big data, the repositories of health information that are becoming more commonplace in healthcare institutions and organizations. [...]
A recent study from MD Anderson Cancer Center provides insight into the ways that cancer cells metastasize. Scientists at The University of Texas MD Anderson Cancer Center have found that cancer cells traveling to other [...]
People around the world acquire life insurance policies for different reasons. It’s a common approach to protect one’s assets and cover debts should any life-changing circumstance occur, such as cancer.
I’ve been struggling to answer that question since I was diagnosed with a rare, malignancy known as gastrointestinal stromal tumor on February 18, 2011. I cannot remember what I am wearing right now without looking [...]
GIST Day of Learning (GDOL), a free event, was held at the University of Miami on Saturday, March 23. Sponsored through the generous support of Bayer, Novartis and Genentech, this event is the second in a series of seminars focusing on the education and support of GIST patients and their families.
The LRG is continually involved in advocacy efforts to increase government spending on cancer research. We have joined forces with other cancer agencies to once again urge New Jersey Governor Chris Christie and the New [...]
The new treatment uses T cells, a type of immune cell that are taken from the patient’s body, genetically modified and then reinfused into the patient. These modified T cells are called chimeric antigen receptor (CAR) T cells. In previous trials with these modified T cells, tumor responses have been modest and they did not persist for long enough after being re-introduced into the patient. Using this second generation CAR T cell, Dr. Carl June and his colleagues at Penn obtained long-lasting persistence once the cells were re-introduced.